- $249.09bn
- $292.40bn
- $36.75bn
Merck gets US FDA nod for first-in-its-class oral cholesterol drug (updated)
Merck's cholesterol pill gets US FDA approval
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings (updated)
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings
Viridian jumps after US FDA approves thyroid eye disease drug
US FDA greenlights Viridian's thyroid eye disease drug (updated)
US FDA greenlights Viridian's eye disease drug
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
U.S. STOCKS ON THE MOVE-Crocs, Amgen, Synaptics
Amgen up after EMA recommends revoking marketing authorization for rare-disease drug
EU regulator backs revoking Amgen's right to sell rare-disease drug (updated)
EMA recommends revoking marketing authorisation for Amgen's rare disease drug
Brief: EMA Recommends Revoking Marketing Authorisation For Tavneos In EU
Factbox: Global drugmakers invest billions to boost US presence
China's Harbour BioMed to focus on another patent case after $20 million damages award